Vivos Therapeutics, Inc. VVOS
Medical/Dental Instruments · IPO 2020 · data as of November 13, 2026
Vivos Therapeutics, Inc. (VVOS) is a healthcare company listed in the US with a market value of about $3M. In the twelve months to June 30, 2026 it had revenue of $21M and net income of -$25M, a net margin of -121.8%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 6% a year, a 5-year average ROIC of -186%.
About Vivos Therapeutics
Vivos Therapeutics is listed in the US and classified in medical/dental instruments, IPO year 2020. Revenue went from $11M in 2019 to $17M in 2025, growth of about 7.4% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 1016% over three years (dilution for shareholders). It spends 1% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Revenue growth above 10% last year
- ROE above 15%
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $21M | $17M | $15M | $14M | $16M | $17M | $13M | $11M |
| Net income | -$25M | -$21M | -$11M | -$14M | -$24M | -$20M | -$12M | -$11M |
| Free cash flow | -$19M | -$18M | -$13M | -$13M | -$21M | -$18M | -$6M | -$6M |
| EPS (diluted) | $-1.90 | $-2.07 | $-2.22 | $-11.14 | $-25.90 | $-23997.20 | $-34995.92 | $-23747.23 |
| Net margin | -121.8% | -121.4% | -74.1% | -98.4% | -148.8% | -120.2% | -92.3% | -94.4% |
| ROIC | — | -132.7% | -82.7% | -378.9% | -274.1% | -59.3% | -52.2% | -1090.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Vivos Therapeutics pay a dividend?
Not currently.
Is Vivos Therapeutics a good stock to buy?
We do not give buy or sell advice. Vivos Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.